Senthil SOCKALINGAM
IQVIA新加坡真实世界洞察亚洲负责人，副总裁
Dr. Senthil Sockalingam has more than a decade of experience in healthcare, including working in high impact positions with key oncology compounds in Asia Pacific and China. He has been involved in clinical development strategies with particular focus on Asia as well as managing medical marketing activities in the region. In addition to the clear understanding of drug development strategies in Asia, Dr. Senthil has led advisory boards and coordinated investigator-led studies for these compounds, and in doing so has built an extensive personal network of experts and key opinion leaders.
Prior to joining IQVIA, Dr. Senthil has held strategic positions with companies such as Genzyme, Bayer Healthcare and Novartis, and managed key oncology and hematology brands in Asia, including Glivec, Afinitor, Exjade, Nexavar and Kogenate. He also led the Asian clinical development strategy, and supported registration, commercialization and competitive intelligence activities to ensure the success of these compounds.
Dr. Senthil received his medical Training from University of Malaya, Malaysia and is a Member of the Australasian College of Pathologists.
